KDELR2's Role in Bladder Cancer Immunotherapy
Author Information
Author(s): Zhao Zhiyi, Jia Hongling, Sun Zhou, Li Yumeng, Liu Lingyun
Primary Institution: The First Hospital of Jilin University
Hypothesis
KDELR2 is a promising therapeutic target in bladder cancer immunotherapy.
Conclusion
KDELR2 promotes bladder cancer cell proliferation, invasion, and migration, indicating its potential as a target for immunotherapy.
Supporting Evidence
- KDELR2 expression correlates with poor survival in bladder cancer patients.
- High KDELR2 levels are associated with increased macrophage infiltration.
- KDELR2 enhances bladder cancer cell proliferation and migration.
- Single-cell RNA sequencing identified distinct tumor cell subpopulations.
- Prognostic analysis revealed KDELR2 as a key factor in patient outcomes.
Takeaway
Researchers found that a protein called KDELR2 helps bladder cancer cells grow and spread, which could be important for new treatments.
Methodology
The study used single-cell RNA sequencing and clinical data to construct an RNA transcriptome map of bladder cancer.
Potential Biases
Potential bias due to the focus on a specific cancer type and small sample size.
Limitations
The study's sample size was small, and it primarily focused on urothelial carcinoma, limiting generalizability.
Participant Demographics
The study included bladder cancer patients with diverse demographic backgrounds.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website